regorafenib

Known as: 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide, Regorafenibum 
An orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2017
05010015020052017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
BACKGROUND There are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses during… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2016
2016
BACKGROUND/AIMS The multikinase inhibitor regorafenib is utilized for the treatment of malignancy. The substance is effective in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Tumour mutational status is an important determinant of the response of metastatic colorectal cancer to targeted… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND In the international randomised phase 3 CORRECT trial (NCT01103323), regorafenib significantly improved overall… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND No treatment options are available for patients with metastatic colorectal cancer that progresses after all approved… (More)
Is this relevant?
2013
2013
PURPOSE We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE Regorafenib is a novel oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Background:In a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumour activity in solid tumour… (More)
  • table 1
  • table 3
  • table 2
  • figure 1
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE Metastatic GI stromal tumor (GIST) is a life-threatening disease with no therapy of proven efficacy after failure of… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Angiogenesis, a critical driver of tumor development, is controlled by interconnected signaling pathways. Vascular endothelial… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?